No OxyContin Comparison? Then No Priority Review For Targiniq ER
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA rejected Purdue’s request for priority review of Targiniq ER because the NDA did not show an improvement in abuse deterrence over the sponsor’s own reformulated OxyContin, but the agency noted advantages to having both formulations available.